Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Early Phase 1
1(33.3%)
3Total
Phase 1(2)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07347860Early Phase 1Recruiting

Clinical Study of (A-319) in the Treatment of Active Rheumatoid Arthritis

Role: collaborator

NCT06400537Phase 1Recruiting

Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus

Role: collaborator

NCT06093698Phase 1Not Yet Recruiting

An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases

Role: lead

All 3 trials loaded